Holen Sie sich die Stockscreener-App
2.75
2.23%
0.06
Handel nachbörslich:
2.75
Schlusskurs vom Vortag:
$2.69
Offen:
$2.68
24-Stunden-Volumen:
1.57M
Relative Volume:
0.85
Marktkapitalisierung:
$395.93M
Einnahmen:
$288.95M
Nettoeinkommen (Verlust:
$-119.03M
KGV:
-3.0539
EPS:
-0.9005
Netto-Cashflow:
$60.67M
1W Leistung:
+35.14%
1M Leistung:
+0.73%
6M Leistung:
-33.25%
1J Leistung:
-67.42%
1-Tages-Spanne:
$2.63
$2.79
1-Wochen-Bereich:
$1.99
$2.79
52-Wochen-Spanne:
$1.665
$9.95
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Vergleichen Sie MRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.75 | 296.59M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2025 Earnings Call Transcript - Insider Monkey
Maravai LifeSciences Holdings Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Maravai Lifesciences Holdings (MRVI) Maintains Buy Rating at RBC Capital with $5.00 Target Price - AInvest
Guggenheim Maintains Hold Rating on Maravai Lifesciences Holdings, Analyst Consensus Sees 85.92% Upside - AInvest
Maravai LifeSciences Announces Cost-Cutting Plan - 富途牛牛
RBC Capital Maintains MRVI Rating, Lowers Price Target | MRVI St - GuruFocus
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal - Investing.com Nigeria
Maravai LifeScience stock maintains Buy rating at Stifel despite guidance withdrawal By Investing.com - Investing.com South Africa
Maravai: RBC Capital Keeps Outperform, Cuts PT to $5 from $7. - AInvest
Maravai Lifesciences Announces Major Organizational Restructuring - MSN
Deutsche Bank Adjusts Maravai Lifesciences Price Target to $4.50 From $5, Maintains Buy Rating - MarketScreener
Maravai signals $50M annualized cost reduction plan as leadership targets positive EBITDA in 2026 - MSN
Maravai LifeSciences Q2 2025 Earnings Call Transcript - MarketBeat
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... - Yahoo Finance
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Maravai LifeSciences Holdings Inc (MRVI) Q2 2025 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Holdings Maintains Buy Rating with $4.25 Price Target - AInvest
Maravai LifeSciences Announces Restructuring Amid Revenue Decline - TipRanks
Maravai LifeSciences' Q2 2025: Key Contradictions in Revenue Dynamics and Strategic Outlook - AInvest
Maravai LifeSciences Reports $50M Annualized Cost Reduction Plan, Targets Positive EBITDA by 2026 - AInvest
Maravai LifeSciences Holdings, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Transcript : Maravai LifeSciences Holdings, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Earnings call transcript: Maravai Lifesciences Q2 2025 sees stock dip despite revenue growth - Investing.com Nigeria
Maravai LifeSciences Cuts Costs As Revenue Slips And Guidance Paused - Finimize
Maravai Lifesciences reports Q2 adjusted EPS (8c), consensus (7c) - TipRanks
Maravai Lifesciences withdraws FY25 guidance - TipRanks
Maravai LifeSciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Maravai Q2 2025 slides: New leadership unveils $50M cost-cutting plan amid losses - Investing.com Canada
Maravai Q2 adjusted EPS misses estimates - MarketScreener
Maravai Lifesciences earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Maravai LifeSciences Announces Organizational Restructuring and Cost Reduction Initiatives Aiming for $50 Million in Annual Savings - Quiver Quantitative
Maravai LifeSciences Reports Second Quarter 2025 Financial Results - GlobeNewswire
Maravai Launches Major $50M Restructuring Plan as New CEO Takes Helm Amid Earnings Challenge - Stock Titan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Sentiment analysis tools applied to Maravai LifeSciences Holdings Inc.Insider Strategy for High Conviction Picks - Newser
Stock Traders Buy Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - Defense World
When is Maravai LifeSciences Holdings Inc. stock expected to show significant growthMaximize returns with strategic stock selection - Jammu Links News
How many analysts rate Maravai LifeSciences Holdings Inc. as a “Buy”Discover stocks with massive upside potential - Jammu Links News
Why is Maravai LifeSciences Holdings Inc. stock attracting strong analyst attentionHigh-yield market plays - Jammu Links News
Is Maravai LifeSciences Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Does Maravai LifeSciences Holdings Inc. stock perform well during market downturnsFree Trend-Following Techniques - Jammu Links News
How does Maravai LifeSciences Holdings Inc. compare to its industry peersSkyrocketing profit margins - Jammu Links News
What are the latest earnings results for Maravai LifeSciences Holdings Inc.Outstanding investment returns - Jammu Links News
Is Maravai LifeSciences Holdings Inc. a growth stock or a value stockCapitalize on fast-moving market trends - Jammu Links News
Has Maravai LifeSciences Holdings Inc. found a price floorWatchlist Generator With Real-Time Entry - Newser
Pattern recognition hints at Maravai LifeSciences Holdings Inc. upsideFree Beginner Friendly Stock Selection Guide - Newser
Is Maravai LifeSciences Holdings Inc. meeting your algorithmic filter criteriaFree Swing Trading Entry Point Signals - Newser
Wells Fargo Reiterates a Buy Rating on Maravai LifeSciences Holdings (MRVI) - Insider Monkey
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
Price momentum metrics for Maravai LifeSciences Holdings Inc. explainedFree Capital Protection Trading Strategies - Newser
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):